Revolution Medicines’ Rasonque gains EC authorisation for pancreatic cancer

​The EC has granted marketing authorisation for Revolution Medicines’ rasonque to treat adult patients with metastatic pancreatic adenocarcinoma who have undergone at least one systemic therapy earlier.

The post Revolution Medicines’ Rasonque gains EC authorisation for pancreatic cancer appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.